Related Experiment Video

Updated: Mar 13, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents

L P Zanaga1, N Miotto1, L C Mendes1

  • 1Divisão de Moléstias Infecciosas Departamento de Clínica Médica, Universidade Estadual de Campinas, Campinas, SP, Brasil.

Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas
|October 27, 2016
PubMed

Insights

Hepatitis C virus genotype 3 is challenging to treat, with varying treatment success rates. Optimal regimens and durations for cirrhotic patients remain uncertain, requiring further research.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) genotype 3 accounts for 30.1% of global chronic infections.
  • HCV genotype 3 presents treatment challenges due to limited options and higher risks of cirrhosis and hepatocellular carcinoma.
  • Lower sustained virological response (SVR) rates are observed in HCV genotype 3 patients compared to other genotypes.

Purpose of the Study:

  • To review current treatment options for Hepatitis C virus genotype 3.
  • To evaluate the efficacy of different drug regimens and treatment durations.
  • To identify optimal therapeutic strategies for HCV genotype 3, particularly in cirrhotic patients.

Main Methods:

  • Review of current literature on HCV genotype 3 treatment.
  • Analysis of SVR rates for various drug combinations including pegylated interferon (PegIFN), sofosbuvir (SOF), daclatasvir (DCV), and ribavirin (RBV).
  • Comparison of treatment outcomes based on patient cirrhosis status and treatment duration.

Main Results:

  • PegIFN, SOF, and RBV for 12 weeks show high SVR (83-100%) but have contraindications and adverse events.
  • SOF plus RBV for 24 weeks yields SVR rates of 82-96% (non-cirrhotic) and 62-92% (cirrhotic).
  • SOF plus DCV has high SVR (94-97%) in non-cirrhotic patients but lower rates (59-69%) in cirrhotic patients, improved by RBV addition or extended duration.

Conclusions:

  • Current treatment regimens for HCV genotype 3 show variable efficacy, especially in cirrhotic patients.
  • The optimal duration and regimen for treating HCV genotype 3 in cirrhotic patients are still under investigation.
  • Further research is needed to establish definitive treatment guidelines for HCV genotype 3 infection, particularly for complex cases involving cirrhosis.

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

31.0K
A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.2K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
295
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
708
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
445
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
556
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.2K